Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Females 18 years of age and older at screening.~2. Term pregnancies of 37 to 42 weeks gestation, scheduled to undergo elective C-section.~3. American Society of Anesthesiology (ASA) physical status 1, 2, or 3.~4. Able to provide informed consent, adhere to the study visit schedule, and complete all study assessments.~Exclusion Criteria:~1. Subjects who, in the opinion of the study site principal investigator, have a high-risk pregnancy.~2. Subjects with a pregnancy-induced medical condition or complication.~3. Subjects with 3 or more prior C-sections.~4. Pre-pregnancy body mass index \>50 kg/m2.~5. Allergy, hypersensitivity, intolerance, or contraindication to any of the study medications.~6. Planned concurrent surgical procedure with the exception of salpingo-oophorectomy or tubal ligation.~7. Severely impaired renal or hepatic function.~8. Subjects at an increased risk for bleeding or a coagulation disorder.~9. Concurrent painful physical condition that may require analgesic treatment in the postsurgical period for pain that is not strictly related to the surgery.~10. Clinically significant medical disease in either the mother or baby that, in the opinion of the investigator, would make participation in a clinical study inappropriate.~11. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.~12. Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug.~13. Previous participation in an EXPAREL study.~14. Any clinically significant event or condition uncovered during the surgery that might render the subject medically unstable or complicate the subject's postsurgical course.~15. Receives the epidural component of combined spinal epidural (CSE) anesthesia during the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Standard of Care Group) (Type: ACTIVE_COMPARATOR): 150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
- Group 2 (Duramorph + EXPAREL TAP) (Type: EXPERIMENTAL): 50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
- Group 3 (EXPAREL TAP) (Type: EXPERIMENTAL): EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.

Based on this trial design, predict the completion outcome and termination type (if applicable).